Eli Lilly (LLY) says long-term use of its blockbuster weight loss therapy Zepbound was linked to lower healthcare costs over time in older adults. Read more here.

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from a real-world study of adults over 55 with overweight or obesity, which found...

Eli Lilly stock has logged very strong gains over the past few years, yet the latest valuation checks send a mixed message about where fair value may sit. The intrinsic value estimate from a Discounted Cash Flow (DCF) model points to a meaningful discount, while the broader set of valuation checks does not present Eli Lilly as an obvious bargain or an obvious premium. Eli Lilly has delivered a return of about 399.8% over the past 5 years, which puts extra focus on whether the current share...

Eli Lilly faces a key test as treatment demand, manufacturing expansion, pipeline execution and access shape its next business phase.

Beyond strong drugs, the stock’s ascent was powered by its notable profitability. You watched Eli Lilly (LLY) climb 76% in a year, crushing the broader market’s 19.3% gain. You probably assume you know why: two drugs, Mounjaro and Zepbound, are generating unprecedented revenue streams.

Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told BioSpace.

Eli Lilly and Novo Nordisk both dominated GLP-1 headlines in Q2 2026, but one company raised guidance while the other announced layoffs, pipeline writedowns, and a dramatic price cut. The split screen tells a story that goes beyond which drug sells more.

Fda clears Roche and Eli Lilly blood test expanding Alzheimer diagnosis Simple blood test aims to widen access to early Alzheimers detection after U.S. approval